Skip to main content
logo
Perspective Therapeutics, Inc. (CATX)
NYSEAMERICAN: CATX · Real-Time Price · USD
2.750
+0.130 (4.96%)
Sep 30, 2026, 4:00 PM EDT - Market closed

Perspective Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Jun '22
Revenue
0.410.881.451.435.42-
Revenue Growth
-66.88%-39.20%1.40%-73.52%--
Gross Profit
-95.77-83.33-40.18-18.912.37-
Operating Income
-125.23-113.56-66.8-40.94-8.8-6.42
Net Income
-116.43-103.12-79.28-46.51-10.76-7.27
Earnings Per Share
-1.25-1.40-1.23-1.74-0.76-0.51
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Jun '22
Cash & Investments
236.88144.74226.929.2443.7655.89
Total Debt
3.963.254.062.55-0.52
Net Cash (Debt)
232.91141.48222.856.6943.7655.37
Net Cash Growth
23.88%-36.51%3232.64%-84.72%-20.97%-12.19%
Net Cash Per Share
2.501.923.460.253.083.90

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Jun '22
Operating Cash Flow
-93.07-82.48-18.29-36.91-10.4-7.71
Capital Expenditures
-28.12-12.75-54.41-1.07-0.28-0.27
Free Cash Flow
-121.19-95.23-72.71-37.99-10.68-7.98
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Jun '22
Gross Margin
----43.71%-
Operating Margin
-30619.07%-12846.61%-4594.02%-2855.02%-162.47%-
Pretax Margin
-28710.02%-11813.12%-5531.43%-2796.79%-156.69%-
Profit Margin
-28467.97%-11665.27%-5452.48%-3243.24%-198.71%-
FCF Margin
-29630.07%-10772.96%-5000.55%-2648.88%-197.28%-

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2022
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Jun '22
Forward PE
-21.5121.5121.5121.5121.51
PS Ratio
767.52231.26148.2878.656.49-